The causative agent of human tuberculosis, Mycobacterium tuberculosis complex (MTBC),
comprises seven phylogenetically distinct lineages associated with different geographical …

Prevalent since pre-history, human tuberculosis—caused by the pathogen Mycobacterium
tuberculosis—remains a major source of death worldwide. Moreover, increasing drug …

Advances in modern sequencing technologies allow us to generate sufficient data to
analyze hundreds of bacterial genomes from a single machine in a single day. This potential …

In drug development, there are typically a series of preclinical studies that must be
completed with new compounds or regimens before use in humans. A sequence of in vitro …

Background Combination therapy is one of the most effective tools for limiting the
emergence of drug resistance in pathogens. Despite the widespread adoption of …

Once considered a phenotypically monomorphic bacterium, there is a growing body of work
demonstrating heterogeneity among Mycobacterium tuberculosis (Mtb) strains in clinically …

Molecular and phylogeographic studies have led to the definition within the Mycobacterium
tuberculosis complex (MTBC) of a number of geotypes and ecotypes showing a preferential …

Metabolism underpins the physiology and pathogenesis of Mycobacterium tuberculosis.
However, although experimental mycobacteriology has provided key insights into the …

The Mycobacterium tuberculosis complex (MTBC) causes tuberculosis (TB) in humans and
various other mammals. The human-adapted members of the MTBC comprise seven …

A potent, noncytotoxic indazole sulfonamide was identified by high-throughput screening of>
100,000 synthetic compounds for activity against Mycobacterium tuberculosis (Mtb). This …